Early dissemination of bevacizumab for advanced colorectal cancer: A prospective cohort study

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Zafar, S Yousuf ^a,b   Malin, Jennifer L ^c,d   Grambow, Steven C ^a,b   Abbott, David H ^b   Schrag, Deborah ^e   Kolimaga, Jane T ^a,b   Zullig, Leah L ^b,f   Weeks, Jane C ^e   Fouad, Mona N ^g   Ayanian, John Z ^h   Wallace, Robert ⁱ   Kahn, Katherine L ^j,k   Ganz, Patricia A ^l   Catalano, Paul ^e   West, Dee W ^m,n   Provenzale, Dawn ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f The University of North Carolina at Chapel Hill   (United States)

^g and Clinical Center   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

^j RAND CORPORATION   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m NORTHERN CALIFORNIA CANCER CENTER   (United States)

ⁿ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; AGING; ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; DRUG APPROVAL; DRUG USE; DRUG UTILIZATION; EARLY INTERVENTION; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SEX DIFFERENCE; COLORECTAL TUMOR; COMORBIDITY; MIDDLE AGED; RISK; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COMORBIDITY; DRUG APPROVAL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES;

EID: 80051636225     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-354     Document Type: Article

References (34)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342. 10.1056/NEJMoa032691, 15175435.
2. Schrag D. The price tag on progress--chemotherapy for colorectal cancer. N Engl J Med 2004, 351(4):317-319. 10.1056/NEJMp048143, 15269308.
3. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006, 33(5 Suppl 10):S26-34.
4. Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun C, Bodurka DC. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 2006, 106(11):2452-2458. 10.1002/cncr.21907, 16639738.
5. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M. Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE). J Clin Oncol 2008, 26(33):5326-5334. 10.1200/JCO.2008.16.3212, 18854571.
6. Cohn AL, Bekaii-Saab T, Bendell JC, Hurwitz H, Kozloff M, Roach N, Tezcan H, Feng S, Sing A, Grothey A, et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). J Clin Oncol (Meeting Abstracts) 2010, 28(15_suppl):3596.
7. Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P, Siegel R, Stewart A, Jemal A. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin 2008, 58(1):9-31. 10.3322/CA.2007.0011, 18096863.
8. Ayanian JZ, Chrischilles EA, Wallace RB, Fletcher RH, Fouad MN, Kiefe CI, Harrington DP, Weeks JC, Kahn KL, Malin JL1, et al. Understanding Cancer Treatment and Outcomes: The Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol 2004, 22(15):2992-2996. 10.1200/JCO.2004.06.020, 15284250.
9. Representativeness of the CanCORS participants relative to Surveillance, Epidemiology & End Results (SEER) Cancer Registries, AcademyHealth Annual Research Meeting. , http://bcb.dfci.harvard.edu/catalano/representativenessAHabstrac15jan08.pdf
10. Fast Stats: An interactive tool for access to SEER cancer statistics. , http://seer.cancer.gov/statfacts/html/colorect.html
11. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004, 291(20):2441-2447. 10.1001/jama.291.20.2441, 15161894.
12. Malin J, Ko C, Ayanian J, Harrington D, Nerenz D, Kahn K, Ganther-Urmie J, Catalano P, Zaslavsky A, Wallace R, et al. Understanding cancer patients' experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey. Supp Care Cancer 2006, 14(8):837-848.
13. Bevacizumab prescribing information. , http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0168lbl.pdf
14. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988, 7(8):889-894. 10.1002/sim.4780070807, 3413368.
15. He Y, Zaslavsky AM, Harrington DP, Catalano PJ, Landrum MB. Imputation in a multiformat and multiwave survey of cancer care. Proc Joint Stat Meetings Am Stat Assoc 2007, 1541-1549.
16. Little RJ, Rubin DB. Statistical Analysis with Missing Data. 2002, Hoboken, NJ: Wiley-Interscience, 2.
17. Muhsin M, Graham J, Kirkpatrick P. Bevacizumab. Nat Rev Drug Discov 2004, 3(12):995-996. 10.1038/nrd1601, 15645606.
18. Good News About Cancer. Seriously. , http://www.businessweek.com/technology/content/jun2004/tc2004063_2435_tc024.htm
19. Glassman RH, Sun AY. Biotechnology: identifying advances from the hype. Nat Rev Drug Discov 2004, 3(2):177-183. 10.1038/nrd1309, 15040581.
20. Kahn KL, Adams JL, Weeks JC, Chrischilles EA, Schrag D, Ayanian JZ, Kiefe CI, Ganz PA, Bhoopalam N, Potosky AL, et al. Adjuvant Chemotherapy Use and Adverse Events Among Older Patients With Stage III Colon Cancer. JAMA 2010, 303(11):1037-1045. 10.1001/jama.2010.272, 2893553, 20233821.
21. Hodgson DC, Fuchs CS, Ayanian JZ. Impact of Patient and Provider Characteristics on the Treatment and Outcomes of Colorectal Cancer. J Natl Cancer Inst 2001, 93(7):501-515. 10.1093/jnci/93.7.501, 11287444.
22. Ayanian JZ, Zaslavsky AM, Fuchs CS, Guadagnoli E, Creech CM, Cress RD, O'Connor LC, West DW, Allen ME, Wolf RE, et al. Use of Adjuvant Chemotherapy and Radiation Therapy for Colorectal Cancer in a Population-Based Cohort. J Clin Oncol 2003, 21(7):1293-1300. 10.1200/JCO.2003.06.178, 12663717.
23. Robinson J, Fox K, Bullano M, Grandy S, . Group tSS Atherosclerosis profile and incidence of cardiovascular events: a population-based survey. BMC Cardiovasc Dis 2009, 9(1):46. Group tSS.
24. Cannon CP, Rhee KE, Califf RM, Boden WE, Hirsch AT, Alberts MJ, Cable G, Shao M, Ohman EM, Steg PG, et al. Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol 2010, 105(4):445-452. 10.1016/j.amjcard.2009.10.014, 20152237.
25. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for Caution with Irinotecan, Fluorouracil, and Leucovorin for Colorectal Cancer. N Engl J Med 2001, 345(2):144-146.
26. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent Panel. J Clin Oncol 2001, 19(18):3801-3807.
27. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26(12):2013-2019. 10.1200/JCO.2007.14.9930, 18421054.
28. Govindarajan A, Coburn NG, Kiss A, Rabeneck L, Smith AJ, Law CHL. Population-Based Assessment of the Surgical Management of Locally Advanced Colorectal Cancer. J Natl Cancer Inst 2006, 98(20):1474-1481. 10.1093/jnci/djj396, 17047196.
29. Krupski TL, Kwan L, Afifi AA, Litwin MS. Geographic and Socioeconomic Variation in the Treatment of Prostate Cancer. J Clin Oncol 2005, 23(31):7881-7888. 10.1200/JCO.2005.08.755, 16204005.
30. Nattinger AB, Gottlieb MS, Veum J, Yahnke D, Goodwin JS. Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med 1992, 326(17):1102-1107. 10.1056/NEJM199204233261702, 1552911.
31. Polsky D, Armstrong KA, Randall TC, Ross RN, Even-Shoshan O, Rosenbaum PR, Silber JH. Variation in Chemotherapy Utilization in Ovarian Cancer: The Relative Contribution of Geography. Health Services Res 2006, 41(6):2201-2218.
32. Smith GL, Xu Y, Shih Y-CT, Giordano SH, Smith BD, Hunt KK, Strom EA, Perkins GH, Hortobagyi GN, Buchholz TA. Breast-Conserving Surgery in Older Patients with Invasive Breast Cancer: Current Patterns of Treatment Across the United States. J Am Coll Surg 2009, 209(4):425-433. e422, 10.1016/j.jamcollsurg.2009.06.363, 19801315.
33. Fairfield KM, Lucas FL, Earle CC, Small L, Trimble EL, Warren JL. Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the medicare population. Cancer 2010, 116(20):4840-4848. 10.1002/cncr.25242, 20578182.
34. Mason A, Drummond M, Ramsey S, Campbell J, Raisch D. Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric?. J Clin Oncol 2010, 28(20):3234-3238. 10.1200/JCO.2009.26.2758, 20498408.